ArticleBasic and clinical neuroscience2025
Highlighting the Role of Neurofilament Light and Medium Polypeptides in Peripheral Diabetic Neuropathy.
Article in Basic and clinical neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Serum Neurofilament Light Chain in Diabetic Polyneuropathy: Associations with Neuropathy Burden, Balance Impairment, and Fear of Falling.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Diabetes mellitus is a chronic disease caused by insulin uptake or deficiency. Side effects of diabetes are numerous, according to the severity of the disease. Diabetes could harm the peripheral nerves, with chronic pain leading to nerve damage known as diabetic neuropathy (DN). Signs and symptoms of DN are sharp pains, numbness, and tingling. Distal symmetric polyneuropathy is the most common nerve injury during DN. Accordingly, this study screens candidate genes related to sural nerve DN (SDN) to find the critical ones. Methods: Gene expression data from diabetic patients with and without progressive sural nerve neuropathy (GSE24290) were included in the analysis. GEO2R was applied to the first step analysis to find the significantly differentially expressed genes (DEGs). The queried significant DEGs, along with their first 100 neighbors, were included in a network using the Cytoscape software. The network was analyzed using the Cytoscape network analysis application, and the central nodes were identified. Results: A total of 26 significant DEGs that were extracted from the gene expression profiles, plus 100 first neighbors, were interacted to form the network. Conclusion:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.